Mission Tumor

Oncology targets, strategies, cancer drug development and personalized medicine

Pages

  • Home
  • Website Use Notice and PDF printing help
Showing posts with label 5FU. Show all posts
Showing posts with label 5FU. Show all posts

Thursday, March 3, 2011

Helping Win Steve Jobs' Pancreatic Cancer Fight For All of US Because iPads Are Not the Only Things That Matter

Yesterday, Steve Jobs once again returned to the world stage to introduce Apple's new iPad2 and once again the spotlight was also put on his ongoing battle with pancreatic cancer. 
Read more »
1 comments
Labels: 5FU, abraxane, afinitor, avastin, bevacizumab, biomarkers, chemotherapy, erlotinib, evoerolimus, FOLFIRI, FOLFIRINOX, gemcitabine, gemzar, pancreatic cancer, presentation, sunitinib, sutent
Older Posts Home
Subscribe to: Posts (Atom)

ShareThis

Most Read 30 day

  • Midline Carcinoma, a Cancer Without a Cure: No More
  • Health Costs of Smoking and Prop 29
  • Cancer Fundraising and Advocacy: Audience Matters
  • Verastem brings CSC target into “sharper” focus
  • How does ARIAD's Ponatinib (Iclusig) Work
  • Cost of Cancer Drug Development, 4 Billion. Cost to Patient, 0.1 Million. Benefit, Priceless! Business Model, Unsustainable
  • Dogs Teaching Us a Thing or Two About Cancer Biology
  • Blog Update

About Me

My photo
View my complete profile

Blog Archive

  • ▼  2015 (1)
    • ▼  Oct 2015 (1)
      • Blog Update
  • ►  2014 (5)
    • ►  Jun 2014 (2)
    • ►  Apr 2014 (2)
    • ►  Jan 2014 (1)
  • ►  2013 (18)
    • ►  Nov 2013 (2)
    • ►  Oct 2013 (4)
    • ►  Sep 2013 (2)
    • ►  Jun 2013 (3)
    • ►  May 2013 (3)
    • ►  Apr 2013 (2)
    • ►  Feb 2013 (2)
  • ►  2012 (33)
    • ►  Oct 2012 (1)
    • ►  Jul 2012 (4)
    • ►  Jun 2012 (10)
    • ►  May 2012 (1)
    • ►  Apr 2012 (6)
    • ►  Mar 2012 (7)
    • ►  Jan 2012 (4)
  • ►  2011 (29)
    • ►  Dec 2011 (8)
    • ►  Nov 2011 (1)
    • ►  Oct 2011 (2)
    • ►  Sep 2011 (2)
    • ►  Jul 2011 (2)
    • ►  Jun 2011 (2)
    • ►  May 2011 (2)
    • ►  Apr 2011 (1)
    • ►  Mar 2011 (3)
    • ►  Feb 2011 (5)
    • ►  Jan 2011 (1)
  • ►  2010 (22)
    • ►  Dec 2010 (4)
    • ►  Nov 2010 (7)
    • ►  Oct 2010 (11)

Visitors since the begining of time

Tags

2DG 5FU aaRSs abiraterone abraxane AE37 afinitor agensys agios AGS-16M8F alk AMD Aminoacyl tRNA synthases AML anastrozole angiogenesis angiogenic switch anti-angiogenesis anti-EGFR anti-EGFR MABs apoptone app arn509 aromasin art astellas avastin aveo basal cell carcinoma bayer BCR-ABL bevacizumab bidil biogen idec biomarkers biosimilars biotech biz bisphosphonates book bortezomib brachytherapy BRAF brca breast cancer bromodomain proteins c-kit CABERNET trial cancer advocacy cancer charity cancer diagnosis cancer genome cancer immunology cancer incidence cancer metabolism cancer moa cancer stem cells cancer survival cancer target canine canSAR carcinogenesis CD80 CDx celgene cervarix cetuximab charity chemotherapy choroidal neovascularization circulating tumor cells clinical trial CML CNV codeine colon cancer comparative oncology conference cornerstone pharma CPI-613 cremophor cripto crizotinib crpc csc CT scan CTC custirsen cyp17A1 database dendreon diabetes diagnosis docetaxel dogs drug cost drug counterfeit drug development drug discovery drug pricing dual HER-2 inhibition earthquake economics egfr EML4-ALK emotional support endothelial cells environmental factors epidemiology erbitux erlotinib ET everolimus evoerolimus exemesrane FAQs fda fda guidance Fn14 focus issue FOLFIRI FOLFIRINOX folkman fulvestrant funding fundraising galiximab gardasil gemcitabine gemzar genentech getifinib giving grants great minds greetings hayw hedgehog hepatocellular carcinoma her2 herbs herceptin ibrutinib IDH1 IL2 immunotherapy INC424 interesting interferon-a ipilimumab Istodax JAK-STAT JAK2 JAK2(V617F) japan jevtana JQ1 JQ2 kgf-1 kidney KRAS lapatinib LBH589 LDH-A leadership legislation lestaurtinib leukemia list literature liver liver cancer Lucentis lung cancer lymphoma maiblog mammography mapk MCT1 mdv3100 medivation meeting report melanoma mesothelioma metastatic midline carcinoma mirna mki Mo99 MPN mTOR mucositis multiple myeloma mutations myc myeloproliferative disorders nexavar ngs nimotuzumab notch NRU NSCLC nuclear medicine oncolytic viruses oncomed onyx oral oral-mucositis ovarian cancer paclitaxel pain palliative care pancreatic cancer panitumumab panobinostat patent patient care pdgf pelifermin pericytes personalized medicine pertuzumab pets Petten pfizer PGx pharmacogenomics phase 2 trial phase 3 trial PHY906 PKM2 PMF politics ponatinib presentation Prop 29 prostate cancer provenge pubmed PV Q and A radiation therapy radiodiagnosis radiotherapy radiotracer raf random finds ranibizumab rare cancers rcc red cross regulatory renal cancer renal cell carcinoma restructuring ret retinal diseases revlimid rituximab romidepsin ruxolitinib s1p screening second cancer SEER registry sendai sequencing side-effects sipuleucel-T skin cancer SMO antagonist social media sorafenib statistics steve jobs sunitinib supreme court sutent systems biology T-DM1 talks tarceva taxol Tc99m TG101348 thalidomide theracim therapeutic mabs thyroid thyroid cancer tivozanib tki tools tosocitinib trastuzumab TrpRS tsunami TTM Boston meeting tumor escape tumor microenvironment tumor models tweak tykerb update uranium vectibix vegf vemurafenib verastem video vismodegib volociximab vorinostat warburg xeloda yervoy zeitgeist Zelboraf Zolinza zytiga

AddThis

AlexaStats

My Blog List

  • Lifehacker
    Turn Your Phone Into a Gaming Console With This $90 Snap-On Controller
  • KevinMD.com
    Locum tenens: Reclaiming purpose, autonomy, and financial freedom in medicine
  • BioCentury
    How Tallon plans to make MHRA a pillar of U.K. life sciences competitiveness
  • Forbes - Pharma & Healthcare
    Epic Faces Antitrust Challenge As Lawsuit Proceeds
  • The Concord Review - Will's Blog
    INDIAN STUDENT
  • Sandwalk
    Endogenous retrovirus sequences can be transcriptionally active: the reality vs. the hype
  • Biotech Blog
    Making Medicines Affordable: The Role of Generics
  • Live with Flair
    To Remind You This Isn’t Home
  • Medgadget
    Plant-Based Soft Medical Robots
  • Xconomy
    Watch ‘Jesus Revolution’ (Free) Online Streaming HBO Here’s How!
  • EurekAlert
    Through the thin-film glass, researchers spot a new liquid phase
  • Cancer Network
    Phase III KEYNOTE-361 Trial Fails to Meet Primary End Points
  • Cancer Stem Cell News
    Examples of Research on CSCs during 2019
  • BIOtech NOW
    Nobody Puts Corn in the Corner
  • Coffee and Sci(ence)
    Molecular control of macroscopic forces drives formation of the vertebrate hindgut.
  • Society of Chemical Industry - News
    Phase 1 of the new SCI website is coming shortly
  • Wolfram|Alpha Blog
    Find All Wolfram News in One Place—The Wolfram Blog
  • PharmaGossip
    Oh dear ASDA
  • Radio Free Meredith
    Sadism, trolley problems and fire ants
  • The IN VIVO Blog
    IN VIVO Blog Is No More.
  • WSJ.com: Health Blog
    Is a Paleo Diet Healthier Than Standard Nutritional Guidelines?
  • Being Cancer Network
    I’m Baaack!
  • The Chart
    1 in 7 suffer from sleep 'drunkenness'
  • The Scientific Cartoonist
    NP-hard
  • Pharma Strategy Blog
    Developing a predictive biomarker for PARP inhibition
  • C&EN's The Haystack
    Roche’s GA101 (obinutuzumab): Engineering an antibody to beat Rituxan
  • Biotech SF
    Stanford team wins $20K for algorithm aimed at Lou Gehrig's disease drug trials
  • pipet2pen
    Handwriting is on the Wall
  • Hematopoiesis
    Stem Cell Autopsy: The first teratoma case unfolded
  • KinasePro
    iKinase
  • The Great Beyond (Nature News)
  • Pharmalot
  • Gary Schwitzer's HealthNewsReview Blog
  • Stand Up To Cancer
  • Tumors Galore
  • CureToday.com
  • StemCellDigest - Cancer
  • Bio Job Blog
Show 10 Show All
Ajay K Malik (c) 2010-2014. Simple theme. Powered by Blogger.